It is generally well tolerated; the main considerations are liver enzyme elevations and infusion-related reactions, and the dose is reduced in moderate hepatic impairment.

Is caspofungin taken as a pill?

No. It is a hospital-administered intravenous infusion, given as a loading dose followed by once-daily maintenance.

Does caspofungin cause kidney damage like amphotericin B?

Nephrotoxicity is not a characteristic effect of caspofungin, which is one reason echinocandins are often better tolerated than amphotericin B.

EMA-approvedaka Cancidas

Caspofungin — Complete Research Guide (2026)

Q: How does caspofungin work?

It inhibits beta-(1,3)-D-glucan synthase, blocking synthesis of a fungal cell-wall component absent from human cells, which kills the fungus.

Last updated 2026-06-30

TL;DR

Caspofungin (also known as Cancidas) is a peptide catalogued under Cyclic & Antimicrobial (Echinocandin). It is described as: β-1,3-glucan synthase. Documented context: Invasive candidiasis/aspergillose. Neutral reference entry; EU status: EU-approved prescription medicine.

What is Caspofungin?

Caspofungin is an echinocandin antifungal - a semisynthetic cyclic lipopeptide - and was the first agent of its class to reach the market (FDA-approved 2001 as Cancidas; also EMA-approved). It is given intravenously in hospital.

It is approved for invasive candidiasis and candidaemia, oesophageal candidiasis, empirical antifungal therapy in persistent fever with neutropenia, and for invasive aspergillosis in patients refractory to or intolerant of other antifungal therapies. Approval is supported by pivotal human non-inferiority randomized controlled trials.

As a regulator-approved medicine with a robust RCT evidence base, its efficacy and safety claims rest on clinical trial data rather than preclinical models.

How does Caspofungin work?

Caspofungin non-competitively inhibits the enzyme beta-(1,3)-D-glucan synthase, blocking synthesis of beta-1,3-glucan, an essential structural polysaccharide of the fungal cell wall that is absent from human cells.

Loss of cell-wall integrity causes osmotic instability and fungal cell death; this fungal-specific target underlies the class's generally favourable tolerability.

What does the research say about Caspofungin?

In a pivotal randomized trial, caspofungin was as effective as amphotericin B deoxycholate for invasive candidiasis and candidaemia, and was better tolerated. ^[1]
For empirical antifungal therapy in persistent fever and neutropenia, caspofungin was at least as effective as liposomal amphotericin B, with fewer drug-related adverse events. ^[2]
As salvage therapy, caspofungin produced favourable responses in invasive aspergillosis in patients refractory to or intolerant of conventional antifungal therapy. ^[3]

Clinical research & studies

The references below are the primary sources cited throughout this guide. Each links directly to PubMed or the regulator. Where evidence is preclinical (animal or in-vitro), that is stated rather than implied.

[1] Comparison of caspofungin and amphotericin B for invasive candidiasis — Mora-Duarte J et al., New England Journal of Medicine 2002. (Double-blind randomized non-inferiority trial)
[2] Caspofungin versus liposomal amphotericin B for empirical antifungal therapy in patients with persistent fever and neutropenia — Walsh TJ et al., New England Journal of Medicine 2004. (Randomized controlled trial)
[3] Efficacy and safety of caspofungin for treatment of invasive aspergillosis in patients refractory to or intolerant of conventional antifungal therapy — Maertens J et al., Clinical Infectious Diseases 2004. (Open-label salvage-therapy study)
[4] A Multicenter, double-blind trial of a high-dose caspofungin treatment regimen versus a standard caspofungin treatment regimen for adult patients with invasive candidiasis — Betts RF et al., Clinical Infectious Diseases 2009. (Double-blind randomized trial)
[5] Echinocandin antifungal drugs — Denning DW et al., Lancet 2003. (Review)

Dosing context

This is not medical advice or a usage recommendation. Dosing figures are reported research context only, cited from the published literature.

Caspofungin is a hospital intravenous antifungal typically given as a higher loading dose on day 1 followed by a fixed once-daily maintenance infusion, with the maintenance dose lowered in moderate hepatic impairment.

This is context only, not a dosing recommendation; antifungal choice, dose and duration are determined by the treating clinician based on the infection, cultures and organ function.

Side effects & safety profile

Caspofungin is generally well tolerated. The most relevant considerations are hepatic - transaminase elevations - and infusion-related reactions (histamine-mediated), so it is given as a slow IV infusion.

The maintenance dose is reduced in moderate hepatic impairment, and drug interactions (for example reduced levels with rifampicin and other inducers) require dose adjustment. Serious hypersensitivity is uncommon.

Because the beta-1,3-glucan target is fungal-specific, class toxicity is low relative to amphotericin B; nephrotoxicity is not a characteristic effect.

Stacking & combinations

Combination antifungal regimens using an echinocandin are a specialist, clinician-directed strategy for selected severe infections and are not a consumer stacking practice.

Finding Caspofungin vendors

This is an independent, neutral directory — we sell nothing and route no purchases. Use it to read regulatory context and (where available) genuine, moderated vendor information for your country.

Choose your country

We never list placeholder vendors. Pick your country to see neutral regulatory context.

Browse the directory

User reviews

No reviews yet

Reviews appear here once submitted and moderated. An aggregate rating is shown only after at least 5 genuine reviews — we never fabricate ratings.

Frequently asked questions

Invasive candidiasis and candidaemia, oesophageal candidiasis, empirical therapy in febrile neutropenia, and invasive aspergillosis in patients refractory to or intolerant of other antifungals.

References

[1] Comparison of caspofungin and amphotericin B for invasive candidiasis — Mora-Duarte J et al., New England Journal of Medicine 2002. PMID: 12490683. View sourceStudy: Double-blind randomized non-inferiority trialCaspofungin was as effective as amphotericin B for invasive candidiasis and better tolerated.
[2] Caspofungin versus liposomal amphotericin B for empirical antifungal therapy in patients with persistent fever and neutropenia — Walsh TJ et al., New England Journal of Medicine 2004. PMID: 15459300. View sourceStudy: Randomized controlled trialCaspofungin was at least as effective as liposomal amphotericin B for empirical therapy, with fewer toxicities.
[3] Efficacy and safety of caspofungin for treatment of invasive aspergillosis in patients refractory to or intolerant of conventional antifungal therapy — Maertens J et al., Clinical Infectious Diseases 2004. PMID: 15578352. View sourceStudy: Open-label salvage-therapy studyCaspofungin gave favourable responses in refractory or intolerant invasive aspergillosis.
[4] A Multicenter, double-blind trial of a high-dose caspofungin treatment regimen versus a standard caspofungin treatment regimen for adult patients with invasive candidiasis — Betts RF et al., Clinical Infectious Diseases 2009. PMID: 19419331. View sourceStudy: Double-blind randomized trialA high-dose regimen was as effective and as safe as the standard caspofungin dose in invasive candidiasis.
[5] Echinocandin antifungal drugs — Denning DW et al., Lancet 2003. PMID: 14550704. View sourceStudy: ReviewReviews the echinocandin class, including caspofungin's beta-1,3-glucan-synthase inhibition and favourable safety.

This article is for educational and research purposes only. Peptides discussed here are not approved for human consumption by the FDA, EMA, or equivalent regulators outside of specific clinical contexts. Always consult a licensed medical professional before any therapeutic use.